Alfa-1-antitrypsinmangel
Research output: Contribution to journal › Journal article › Research › peer-review
Documents
- Fulltext
Final published version, 309 KB, PDF document
The subject of this review is alpha-1-antitrypsin deficiency (A1AD), which is a rare hereditary disease with great impact in adults, especially smokers, quality of life and longevity. Early diagnosis is crucial for treatment outcome. The primary care physician should refer patients younger than 50-years-old with COPD or emphysema, familiar accumulation of A1AD or liver cirrhosis of unknown cause. Most important treatment is smoking cessation, pulmonary rehabilitation and inhaled medication according to current guidelines. Substitution treatment with alpha-1-antitrypsin is now an option after its approval by the Danish medical council in January 2020.
Translated title of the contribution | Alpha-1-antitrypsin deficiency |
---|---|
Original language | Danish |
Article number | V02210150 |
Journal | Ugeskrift for Laeger |
Volume | 183 |
Issue number | 30 |
Number of pages | 7 |
ISSN | 0041-5782 |
Publication status | Published - 2021 |
Links
ID: 288056330